BiotechTube

UBX0101 or placebo

Pre-clinicalTerminated
1 views this week 0 watching💤 Quiet
Interest: 8/100
8
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Knee Osteoarthritis

Conditions

Knee Osteoarthritis

Trial Timeline

Apr 20, 2020 → Nov 2, 2020

NCT ID
NCT04349956

About UBX0101 or placebo

UBX0101 or placebo is a pre-clinical stage product being developed by Unity Biotechnology for Knee Osteoarthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04349956. Target conditions include Knee Osteoarthritis.

What happened to similar drugs?

11 of 20 similar drugs in Knee Osteoarthritis were approved

Approved (11) Terminated (0) Active (9)
✅NISEDr. Reddy's LaboratoriesApproved
✅Capsaicin Topical SolutionAstellas PharmaApproved
✅ImrecoxibJiangsu Hengrui MedicineApproved
✅celecoxibPfizerApproved
✅Ibuprofen + Placebo + CelecoxibPfizerApproved
✅Celecoxib + Naproxen + PlaceboPfizerApproved
✅Celecoxib + PlaceboPfizerApproved

Hype Score Breakdown

Clinical
3
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04349956Pre-clinicalTerminated

Competing Products

20 competing products in Knee Osteoarthritis

See all competitors
ProductCompanyStageHype Score
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
LY2828360 + PlaceboEli LillyPhase 2
35
UBX0101Unity BiotechnologyPhase 1
19
UBX0101Unity BiotechnologyPhase 2
25
UBX0101Unity BiotechnologyPhase 1
19
YH23537 + Celecoxib + YH23537 placeboYuhanPhase 2
35
YM150 + WarfarinAstellas PharmaPhase 2
35
ASP7962 + Naproxen + PlaceboAstellas PharmaPhase 2
35
Capsaicin Topical SolutionAstellas PharmaApproved
43
CGS-200-1 + CGS-200-5 + CGS-200 VehicleAstellas PharmaPhase 2
35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + PlaceboSun PharmaceuticalPhase 2
35
Duloxetine + PlaceboShionogiPhase 3
40
DuloxetineShionogiPhase 3
40
V120083 + Naproxen + PlaceboShionogiPhase 2
35
ONO-4474 + Placebo matching ONO-4474Ono PharmaceuticalPhase 2
27
Duloxetine + PlaceboEli LillyPhase 3
40
Duloxetine (DLX) + Placebo (PLA)Eli LillyPhase 3
40
Duloxetine + placeboEli LillyPhase 3
40
Placebo + LY545694 49 mg + LY545694 105 mgEli LillyPhase 2
35